Corvus Pharma Com (CRVS) Stock Price, Quote & News

Latest News on CRVS

Jan 13, 2025, 7:30 AM EST - 4 days ago

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jan 7, 2025, 4:01 PM EST - 10 days ago

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 1:36 PM EST - 4 weeks ago

Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting

Dec 18, 2024, 1:23 PM EST - 4 weeks ago

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

Dec 18, 2024, 8:42 AM EST - 4 weeks ago

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

HEI TSLA

Dec 18, 2024, 7:30 AM EST - 4 weeks ago

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Dec 17, 2024, 4:01 PM EST - 4 weeks ago

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Dec 4, 2024, 4:05 PM EST - 6 weeks ago

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Nov 14, 2024, 10:01 AM EST - 2 months ago

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Nov 13, 2024, 1:18 PM EST - 2 months ago

Corvus Pharmaceuticals: The Market Likes The Story

Nov 13, 2024, 12:02 AM EST - 2 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:01 PM EST - 2 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 9, 2024, 1:40 PM EST - 2 months ago

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Nov 5, 2024, 4:02 PM EST - 2 months ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Sep 17, 2024, 8:00 AM EDT - 4 months ago

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

$Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma$

Sep 10, 2024, 8:30 AM EDT - 4 months ago

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Sep 3, 2024, 4:05 PM EDT - 4 months ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 7:03 AM EDT - 4 months ago

Corvus Pharmaceuticals Eyes Phase 3 Trials: Soquelitinib's Promise In PTCL

Aug 9, 2024, 10:22 PM EDT - 5 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:01 PM EDT - 5 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

$Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)$